What are KOLs opinions of pipeline long-acting injectable GLP-1 agonists, Eli Lilly’s Trulicity (dulaglutide) and Novo Nordisk’s Stage III product, semaglutide?
What factors will certainly drive the uptake of injectable GLP-1 antagonists as better option within this procedure class emerges, and Exactly what barriers will certainly this class go on to face?
What comes to do KOLs have actually Sanofi’s LixiLan (insulin glargine and the GLP-1, lixisenatide fixed dose combination)?
Where are the potential possibilities with basal insulin/GLP-1 combinations and Exactly what are the important strategic considerations?
How is Eli Lilly’s Basaglar/Abasaglar most likely to influence when it come to the usage of current basal insulins such as Sanofi’s Lantus, Novo Nordisk’s Tresiba (insulin degludec) and Sanofi’s Toujeo?
Update Bulletins contain expert recommendations and analysis based when it come to FirstWord analyst re-engagement along with the KOLs after serious occasions such as product approvals, essential data releases and serious conferences to deliver the a lot of beneficial insights along with every update.
Download the complete report: http://ift.tt/20BkzRm
About Reportbuyer
Reportbuyer is a top area intelligence program that offers all of deal study reports from leading publishers
http://ift.tt/ORNIX1
For much more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To see the original version when it come to PR Newswire, visit:http://ift.tt/22tVYxk
SOURCE ReportBuyer
